Prevalence, Predictors of Interval Colorectal Cancer ID'd

This article originally appeared here.
Share this content:
Prevalence, Predictors of Interval Colorectal Cancer ID'd
Prevalence, Predictors of Interval Colorectal Cancer ID'd

FRIDAY, June 8 (HealthDay News) -- A variety of procedural and biologic factors contribute to the development of interval colorectal cancers, seen in 7.2 percent of Medicare beneficiaries, according to a study published in the June 15 issue of Cancer.

Gregory S. Cooper, M.D., of the University Hospitals Case Medical Center in Cleveland, and colleagues identified 57,839 patients aged 69 and older diagnosed with colorectal cancer from the linked Surveillance, Epidemiology, and End Results-Medicare database. The frequency and predictors of colorectal cancer cases that develop after a negative colonoscopy (interval cancer) were assessed.

The researchers found that the overall prevalence of interval cancer was 7.2 percent. Proximal tumor location, increased comorbidity, a previous diagnosis of diverticulosis, and having previously undergone a polypectomy all correlated significantly with interval cancer. At the level of the endoscopist, significant risk factors for interval cancer included lower polypectomy rate, higher colonoscopy volume, and specialty other than gastroenterology.

"A significant proportion of patients developed interval colorectal cancer, particularly in the proximal colon," the authors write. "Contributing factors likely included both procedural and biologic factors, emphasizing the importance of meticulous examination of the mucosa."

Full Text (subscription or payment may be required)

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs